

OPEN ACCESS

EDITED BY
Javier Echeverria,
University of Santiago, Chile

REVIEWED BY Dâmaris Silveira, University of Brasilia, Brazil

*CORRESPONDENCE Mojtaba Heydari, mheydari@sums.ac.ir

SPECIALTY SECTION

This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology

RECEIVED 03 June 2022 ACCEPTED 18 July 2022 PUBLISHED 16 August 2022

CITATION

Heydari M, Rauf A, Thiruvengadam M, Chen X and Hashempur MH (2022), Editorial: Clinical safety of natural products, an evidence-based approach. *Front. Pharmacol.* 13:960556. doi: 10.3389/fphar.2022.960556

COPYRIGHT

© 2022 Heydari, Rauf, Thiruvengadam, Chen and Hashempur. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Editorial: Clinical safety of natural products, an evidence-based approach

Mojtaba Heydari^{1*}, Abdur Rauf², Muthu Thiruvengadam³, Xiao Chen⁴ and Mohammad Hashem Hashempur⁵

¹Persian Medicine Network (PMN), Universal Scientific Education and Research Network (USERN), Shiraz University of Medical Sciences, Shiraz, Iran., ²Department of Chemistry, University of Swabi, Swabi, Pakistan, ³Department of Crop Science, College of Sanghuh Life Science, Konkuk University, Seoul, South Korea, ⁴Department of Orthopedic Trauma, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China, ⁵Research Center for Traditional Medicine and History of Medicine, Department of Persian Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

KEYWORDS

natural products, herbal medicine, Persian medicine, safety, side effect, toxicity

Editorial on the Research Topic

Clinical safety of natural products, an evidence-based approach

There is increasing use of natural products including medicinal plants, phytopharmaceuticals, nutraceuticals, vitamins, and nutritional supplements for different health purposes worldwide (Mosavat et al., 2018). It is generally believed that these products are safe (Lynch and Berry, 2007). However, there is growing evidence of safety concerns associated with these natural products (Haq, 2004). Nevertheless, little is known about the adverse events associated with these products (Bent, 2008).

There are different concerns regarding the safety of natural products. The complexity in the nature of these formulations is one of the sources of concern (Capasso et al., 2003). Not only compound herbal formulations, but also simple herbal drugs have many biologically active ingredients which may have toxic effects. The interaction of the multiple herbs in a formulation and multiple ingredients in one herb with each other, make the safety evaluation more difficult than in chemical medicines. Besides the potential intrinsic toxicity of the natural products, extrinsic toxicity is another source of concern. For example, heavy metals are found at higher than standard levels in many herbal formulations on the market (Keshvari et al., 2021). Inaccurate identification of the used medicinal plants and their use in wrong clinical indications are other source of the safety issues. And the last point is the drug interactions between the natural products and chemical medicines taken by the patients (Ghosh et al., 2018).

Different methods have been popularly used to evaluate the safety of natural products. *In-vitro* and *in vivo* studies evaluating the toxicities of different cells and organs are among these methods. However, applying these data in clinical practice faces multiple limitations. Besides these traditional methods, different types of research including clinical safety

Heydari et al. 10.3389/fphar.2022.960556

studies and pharmacovigilance-based investigations can help us to have an evidence-based approach to the safety of these products (Raoufinejad et al., 2020). Information presented as associated adverse events of these products gathered from pharmacovigilance systems needs to be analyzed by scientific methods to determine the significance and potential causal relationship. The identification of adverse events associated with the use of natural products is challenging due to different reasons including impurities, batch-to-batch variability, misidentification and/or labeling, and different source of used production materials. There are also concerns about the suitable working of classic reporting systems in gathering reports on adverse events on unregulated medicines and supplements including so-called borderline products.

By collecting articles on this theme, we tried to develop information about the safety of natural products to enhance their proper use in the general population. In this regard, we focused on clinical, and epidemiologic studies in this field. Studies published in this research topic focused on the safety of medicinal use of multiple medicinal plants (*Tripterygium wilfordii, Entada abyssinica,* and *Brucea javanica*) and nutritional supplements (coffee and cinnamon) as natural products. We need to expand the scientific data on the clinical safety of natural products help us with evidence-based decision making on their proper use.

References

Bent, S. (2008). Herbal medicine in the United States: Review of efficacy, safety, and regulation: Grand rounds at university of California, san francisco medical center. *J. Gen. Intern. Med.* 23 (6), 854–859. doi:10.1007/s11606-008-0632-y

Capasso, F. Gaginella, T. S. Grandolini, G., and Izzo, A. A. (2003). *The complexity of herbal medicines*. Phytotherapy: Springer, 11–12.

Ghosh, N. Ghosh, R. C. Kundu, A., and Mandal, S. C. (2018). Herb and drug interaction. Natural products and drug discovery. Elsevier, 467–490.

Haq, I. (2004). Safety of medicinal plants. Pak J. Med. Res. 43 (4), 203-210.

Keshvari, M., Nedaeinia, R., Nedaeinia, M., Ferns, G. A., Nia, S. N., and Asgary, S. (2021). Assessment of heavy metal contamination in herbal medicinal products consumed in the Iranian market. *Environ. Sci. Pollut. Res.* 28 (25), 33208–33218. doi:10.1007/s11356-021-13020-7

Author contributions

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Lynch, N., and Berry, D. (2007). Differences in perceived risks and benefits of herbal, over-the-counter conventional, and prescribed conventional, medicines, and the implications of this for the safe and effective use of herbal products. *Complement. Ther. Med.* 15 (2), 84–91. doi:10.1016/j.ctim.2006.06.007

Mosavat, S. H., Heydari, M., Hashempur, M. H., and Dehghani, S. M. (2018). Use of complementary and alternative medicine among paediatric patients with hepatogastrointestinal diseases. *East. Mediterr. health J. = La revue de sante de Mediterr. Orient. = al-Majallah al-sihhiyah li-sharq al-mutawassit* 24 (10), 1018–1025. doi:10.26719/2018.24.10.1018

Raoufinejad, K., Gholami, K., Javadi, M., Rajabi, M., Torkamandi, H., Moeini, A., et al. (2020). A retrospective cohort study of herbal medicines use during pregnancy: Prevalence, adverse reactions, and newborn outcomes. *Traditional Integr. Med.*, 70–85. doi:10.18502/tim.v5i2.3627